Resource Summary Report

Generated by RRID on Aug 7, 2026

Ultra-LEAF™ Purified anti-mouse CD3?

RRID:AB_11149115
Type: Antibody

Proper Citation

(BioLegend Cat# 100340, RRID:AB_11149115)

Antibody Information

URL: http://antibodyregistry.org/AB_11149115

Proper Citation: (BioLegend Cat# 100340, RRID:AB_11149115)

Target Antigen: CD3epsilon

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: FC, IHC-F, IP, Activ, Block, WB, ICC

Antibody Name: Ultra-LEAF™ Purified anti-mouse CD3?

Description: This monoclonal targets CD3epsilon

Target Organism: mouse

Clone ID: Clone 145-2C11

Antibody ID: AB_11149115

Vendor: BioLegend

Catalog Number: 100340

Alternative Catalog Numbers: 100360, 100371, 100372, 100339, 100359

Record Creation Time: 20260526T044339+0000

Record Last Update: 20260526T044339+0000

Ratings and Alerts

No rating or validation information has been found for Ultra-LEAF™ Purified anti-mouse CD3?.

No alerts have been found for Ultra-LEAF™ Purified anti-mouse CD3?.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 91 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Wang H, et al. (2026) Neutrophil Antigen Presentation Reprograms the Tumor Microenvironment and Elicits Durable and Broad Antitumor Immunity. Cancer research communications, 6(3), 500.

Philbrook P, et al. (2026) Medium-Chain Fatty Acid Receptor GPR84 Modulates Cytotoxic CD8 T-cell Antitumor Immunity through Metabolic Reprogramming. Cancer immunology research, 14(4), 640.

Chemla Y, et al. (2026) HLA export by melanoma cells decoys cytotoxic T cells to promote immune evasion. Cell, 189(1), 233.

Wang Y, et al. (2026) Tuning the sensitivity of mechanosensory receptors through histidine scanning. Cell, 189(6), 1680.

Yao B, et al. (2026) Divergent tumor immunity determined by bacteria-cancer cell engagement. Cell, 189(6), 1748.

Murakami R, et al. (2026) Foxp3 and BATF cooperatively direct cis-regulatory programs and gene expression for effector Treg cell differentiation. Immunity, 59(5), 1253.

Mochizuki-Ono C, et al. (2026) PLA2G12A-driven extracellular vesicle-lipid signaling amplifies pathogenic T cell responses in inflammatory diseases. Cell reports, 45(6), 117391.

Giacomantonio MA, et al. (2026) Subversion of kynurenine-induced AHR activation in CD8 T cells by kynureninase-expressing antigen-presenting cells. Cell reports, 45(4), 117149.

Kourtesakis A, et al. (2026) A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. Molecular therapy. Oncology, 34(1), 201134.

De la Torre Medina J, et al. (2026) Immunomodulation of Pancreatic Cancer via Inhibition of SUMOylation and the CD155/TIGIT Pathway. Molecular cancer therapeutics, 25(6), 957.

Pang J, et al. (2026) Law-NQO1 redox boosts the pentose phosphate pathway to confer stem-like properties and antitumor durability in effector CD8+ T cells. Cell chemical biology, 33(3), 321.

Yang S, et al. (2026) Oat-?-glucan potentiates anti-PD-1 efficacy through Faecalibacterium prausnitzii-derived butyrate and indole-3-propionic acid. Cell host & microbe, 34(7), 1333.

Tripathi A, et al. (2026) Protocol for intranuclear Nrf2 detection in activated mouse, human, and Jurkat T cells by spectral flow cytometry. STAR protocols, 7(1), 104360.

Li X, et al. (2026) The TCR-SUB1-DOCK2 axis promotes autoimmunity by driving pathogenic CD4+ T cell tissue infiltration. Immunity, 59(1), 98.

Zhang P, et al. (2026) Sympathetic-epithelial crosstalk governs tissue-resident memory T cell immunosurveillance in the skin. Cell, 189(5), 1323.

Kureshi CTS, et al. (2026) Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Cancer cell, 44(7), 1381.

Song H, et al. (2025) Targeting tumor monocyte-intrinsic PD-L1 by rewiring STING signaling and enhancing STING agonist therapy. Cancer cell, 43(3), 503.

Brown ME, et al. (2025) Inhibition of CD226 co-stimulation suppresses diabetes development in the NOD mouse by augmenting regulatory T cells and diminishing effector T cell function. Diabetologia, 68(2), 397.

Hirade K, et al. (2025) Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy. Cell reports. Medicine, 6(9), 102317.

Li H, et al. (2025) T cell-intrinsic cGAS-CTCF regulation maintains regulatory T cell development and function. Cell reports, 44(10), 116302.